Cargando…

Ocular surface disease: a known yet overlooked side effect of topical glaucoma therapy

Ocular surface disease (OSD), a disorder affecting the lacrimal and meibomian glands and the corneal and conjunctival epithelium, is a well-known complication of topical glaucoma therapy. OSD can present as a new or pre-existing condition that virtually any anti-glaucoma formulation can exacerbate....

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz-Lozano, Raul E., Azar, Nadim S., Mousa, Hazem M., Quiroga-Garza, Manuel E., Komai, Seitaro, Wheelock-Gutierrez, Lorena, Cartes, Cristian, Perez, Victor L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403269/
https://www.ncbi.nlm.nih.gov/pubmed/37547228
http://dx.doi.org/10.3389/ftox.2023.1067942
_version_ 1785085031174111232
author Ruiz-Lozano, Raul E.
Azar, Nadim S.
Mousa, Hazem M.
Quiroga-Garza, Manuel E.
Komai, Seitaro
Wheelock-Gutierrez, Lorena
Cartes, Cristian
Perez, Victor L.
author_facet Ruiz-Lozano, Raul E.
Azar, Nadim S.
Mousa, Hazem M.
Quiroga-Garza, Manuel E.
Komai, Seitaro
Wheelock-Gutierrez, Lorena
Cartes, Cristian
Perez, Victor L.
author_sort Ruiz-Lozano, Raul E.
collection PubMed
description Ocular surface disease (OSD), a disorder affecting the lacrimal and meibomian glands and the corneal and conjunctival epithelium, is a well-known complication of topical glaucoma therapy. OSD can present as a new or pre-existing condition that virtually any anti-glaucoma formulation can exacerbate. As such, both glaucoma and OSD frequently coexist. Typical OSD symptoms include ocular discomfort, redness, burning, and dryness, whereas signs include periorbital and eyelid skin pigmentation, conjunctival scarring, and superficial punctate keratitis. Pressure-lowering eyedrops can cause toxic, allergic, and inflammatory reactions on the ocular surface. The latter can result from either preservatives or direct toxicity from the active molecule. Although usually mild, OSD can cause significant symptoms that lead to poor quality of life, decreased compliance to therapy, glaucoma progression, and worse visual outcomes. Given the chronic nature of glaucoma, lack of curative therapy, and subsequent lifelong treatment, addressing OSD is necessary. This manuscript aims to provide an up-to-date overview of OSD’s signs, symptoms, and pathogenic mechanisms from glaucoma therapy toxicity.
format Online
Article
Text
id pubmed-10403269
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104032692023-08-05 Ocular surface disease: a known yet overlooked side effect of topical glaucoma therapy Ruiz-Lozano, Raul E. Azar, Nadim S. Mousa, Hazem M. Quiroga-Garza, Manuel E. Komai, Seitaro Wheelock-Gutierrez, Lorena Cartes, Cristian Perez, Victor L. Front Toxicol Toxicology Ocular surface disease (OSD), a disorder affecting the lacrimal and meibomian glands and the corneal and conjunctival epithelium, is a well-known complication of topical glaucoma therapy. OSD can present as a new or pre-existing condition that virtually any anti-glaucoma formulation can exacerbate. As such, both glaucoma and OSD frequently coexist. Typical OSD symptoms include ocular discomfort, redness, burning, and dryness, whereas signs include periorbital and eyelid skin pigmentation, conjunctival scarring, and superficial punctate keratitis. Pressure-lowering eyedrops can cause toxic, allergic, and inflammatory reactions on the ocular surface. The latter can result from either preservatives or direct toxicity from the active molecule. Although usually mild, OSD can cause significant symptoms that lead to poor quality of life, decreased compliance to therapy, glaucoma progression, and worse visual outcomes. Given the chronic nature of glaucoma, lack of curative therapy, and subsequent lifelong treatment, addressing OSD is necessary. This manuscript aims to provide an up-to-date overview of OSD’s signs, symptoms, and pathogenic mechanisms from glaucoma therapy toxicity. Frontiers Media S.A. 2023-07-21 /pmc/articles/PMC10403269/ /pubmed/37547228 http://dx.doi.org/10.3389/ftox.2023.1067942 Text en Copyright © 2023 Ruiz-Lozano, Azar, Mousa, Quiroga-Garza, Komai, Wheelock-Gutierrez, Cartes and Perez. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Toxicology
Ruiz-Lozano, Raul E.
Azar, Nadim S.
Mousa, Hazem M.
Quiroga-Garza, Manuel E.
Komai, Seitaro
Wheelock-Gutierrez, Lorena
Cartes, Cristian
Perez, Victor L.
Ocular surface disease: a known yet overlooked side effect of topical glaucoma therapy
title Ocular surface disease: a known yet overlooked side effect of topical glaucoma therapy
title_full Ocular surface disease: a known yet overlooked side effect of topical glaucoma therapy
title_fullStr Ocular surface disease: a known yet overlooked side effect of topical glaucoma therapy
title_full_unstemmed Ocular surface disease: a known yet overlooked side effect of topical glaucoma therapy
title_short Ocular surface disease: a known yet overlooked side effect of topical glaucoma therapy
title_sort ocular surface disease: a known yet overlooked side effect of topical glaucoma therapy
topic Toxicology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403269/
https://www.ncbi.nlm.nih.gov/pubmed/37547228
http://dx.doi.org/10.3389/ftox.2023.1067942
work_keys_str_mv AT ruizlozanoraule ocularsurfacediseaseaknownyetoverlookedsideeffectoftopicalglaucomatherapy
AT azarnadims ocularsurfacediseaseaknownyetoverlookedsideeffectoftopicalglaucomatherapy
AT mousahazemm ocularsurfacediseaseaknownyetoverlookedsideeffectoftopicalglaucomatherapy
AT quirogagarzamanuele ocularsurfacediseaseaknownyetoverlookedsideeffectoftopicalglaucomatherapy
AT komaiseitaro ocularsurfacediseaseaknownyetoverlookedsideeffectoftopicalglaucomatherapy
AT wheelockgutierrezlorena ocularsurfacediseaseaknownyetoverlookedsideeffectoftopicalglaucomatherapy
AT cartescristian ocularsurfacediseaseaknownyetoverlookedsideeffectoftopicalglaucomatherapy
AT perezvictorl ocularsurfacediseaseaknownyetoverlookedsideeffectoftopicalglaucomatherapy